Maternal mortality: one death every 7 min

The Lancet

Volumn 375, Issue 9728, 2010, Pages 1762-1763

  Potts, Malcolm ^a   Prata, Ndola ^a   Sahin Hodoglugil, Nuriye Nalan ^b  

^a Health and Sustainability   (United States)

^b Venture Strategies Innovations   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MISOPROSTOL; OXYTOCIN;

ARTICLE; CHILD DEATH; CHILDBIRTH; CHILL; DRUG COST; DRUG FATALITY; DRUG SAFETY; FEVER; HUMAN; LABOR STAGE 3; MATERNAL MORTALITY; OBSTETRIC CARE; POSTPARTUM HEMORRHAGE; PRIORITY JOURNAL; UTERUS CONTRACTION;

EID: 77952350761     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(10)60750-7     Document Type: Note

References (12)

1. Widmer M., Blum J., Hofmeyr G.J., et al. Misoprostol as an adjunct to standard uterotonics for treatment of post-partum haemorrhage: a multicentre, double-blind randomised trial. Lancet 375 (2010) 1808-1813
2. Blum J., Winikoff B., Raghavan S., et al. Treatment of post-partum haemorrhage with sublingual misoprostol versus oxytocin in women receiving prophylactic oxytocin: a double-blind, randomised, non-inferiority trial. Lancet 375 (2010) 217-223
3. Winikoff B., Dabash R., Durocher D., et al. Treatment of post-partum haemorrhage with sublingual misoprostol versus oxytocin in women not exposed to oxytocin during labour: a double-blind, randomised, non-inferiority trial. Lancet 375 (2010) 210-216
4. Rajbhandari S., Hodgins S., Sanghvi H., McPherson R., Pradhan Y.V., Baqui A.H., and Misoprostol Study Group. Expanding uterotonic protection following childbirth through community-based distribution of misoprostol: operations research study in Nepal. Int J Gynecol Obstet 108 (2010) 282-288
5. Sanghvi H., Ansari N., Prata J.V.N., Gibson H., Ehsan A., and Smith J. Prevention of postpartum hemorrhage at home birth in Afghanistan. Int J Gynecol Obstet 108 (2010) 276-281
6. Prata N., Mbaruku G., Campbell M., Potts M., and Vahidnia F. Controlling postpartum hemorrhage after home births in Tanzania. Int J Gynecol Obstet 90 (2005) 51-55
7. International Confederation of Midwives, and International Federation of Gynaecology and Obstetrics. Prevention and treatment of post-partum haemorrhage: new advances for low resource settings. Joint statement (November, 2006). http://www.pphprevention.org/files/FIGO-ICM_Statement_November2006_Final.pdf (accessed April 4, 2010).
8. Department of Making Pregnancy Safer, and WHO. WHO recommendations for the prevention of postpartum haemorrhage (2007). http://whqlibdoc.who.int/hq/2007/WHO_MPS_07.06_eng.pdf (accessed April 12, 2010).
9. Department of Reproductive Health and Research, and WHO. WHO statement regarding the use of misoprostol for postpartum haemorrhage prevention and treatment (2009). http://whqlibdoc.who.int/hq/2009/WHO_RHR_09.22_eng.pdf (accessed April 12, 2010).
10. Gülmezoglu A.M., Villar J., Ngoc N.T.N., et al., for the WHO Collaborative Group To Evaluate Misoprostol in the Management of the Third Stage of Labour. WHO multicentre randomised trial of misoprostol in the management of the third stage of labour. Lancet 358 (2001) 689-695
11. Prata N., Hamza S., Gypson R., Nada K., Vahidnia F., and Potts M. Misoprostol and active management of the third stage of labor. Int J Gynecol Obstet 94 (2006) 149-155
12. Prata N., Sreenivas A., Vahidnia F., and Potts M. Saving maternal lives in resource-poor settings: facing reality. Health Policy 89 (2009) 131-148